Business Wire

FL-KNOWBE4

Share
KnowBe4’s Team of Cybersecurity Experts Release Predictions for 2022

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, today announced its 2022 cybersecurity predictions from its team of industry experts.

The predicted cybersecurity trends for 2022 include:

  • Nuclear Ransomware 3.0
    A trend that is currently building for the future on the side of the bad actor is that ransomware gangs are morphing into "everything gangs." Instead of just doing ransomware and data exfiltration, they are doing cryptomining, botnet creation, DDoS attacks, etc. The attack gangs of the future will look at every new victim as a pot of gold and try to figure out what to do and in which order to maximize financial value extraction.
  • New Malware Family: Not the Kind You Would Welcome Into Your Home
    A new dangerous and persistent metamorphic malware family called “Tardigrade” is a new strain of Windows malware. It can constantly adapt to avoid detection and was first found targeting the biotech industry, including the infrastructure behind vaccine manufacturing, according to security researchers. This “metamorphic” ability prevents the malware from leaving a consistent signature behind, making it very hard for antivirus programs to spot. It contains the sneaky ability to spread both via phishing emails and USB devices.
  • Virtually Pwned
    Meta, the brand formerly known as Facebook, will entice masses to join the Metaverse. This will spawn a rush to establish dominance in the virtual world. As a result, hackers will also be drawn into this world, and we will see virtual attacks against both individuals and organizations. We will see an explosion of bad things happen to people and resources in the virtual world…virtual looting, virtual theft, account takeovers and more creative criminal exploits.
  • Disinformation Powered by Deep Fakes Will Cause a Political/Financial Circus
    We will see a coordinated disinformation campaign that will rely heavily on deep fakes and manipulated footage to cause a political/financial circus. A deep fake could be used to manipulate a certain political party’s views by stating false opinions, promises or beliefs of a particular candidate. This could cause a chain reaction of certain organizations pulling funds from a political campaign based on statements made by the deep fake.
  • An Attack Against Cryptocurrency Will Hit Real World Economies
    A major cryptocurrency will be attacked, causing billions of dollars in lost value either through direct theft or in value loss. Many individuals and organizations will be severely impacted and it will be referred to as the Black Crypto Day.
  • A Major EU Power Station/Utility Provider Will Be Crippled in a Novel Way Other Than Ransomware
    Most likely somewhere in Eastern Europe, we will see some bad actors cut off your power, your gas and your water. Then as you watch in horror as your phone, tablets and laptop batteries die, they will hand out an olive branch that many will be ready to accept, but at what cost?
  • Someone Will Hack Back the Wrong Bad Actor and Trigger an International Incident
    An overly-eager security researcher will think they have identified the culprit behind a major attack. In an act of retaliation, they will hack back only to discover they did not attribute the attack correctly. This will cause a major international incident and the organization responsible will be placed under extreme scrutiny.
  • The Rise of Dark Economy M&A
    A lot of criminal gangs have become extremely wealthy. In fact, some shady organizations are large enough to be listed on a stock exchange. So, we will see a more formalized dark economy emerge with some M&A activity taking place as some gangs will look to cash-in by selling their organization while others look to grow in capability and reach.
  • When AI Goes Wrong In 2022
    We’ll see the first wave of intelligent attack bots. The future is good threat hunting bots versus bad bots and the best algorithm wins.

“In many ways, it seems as if things are getting worse for cybersecurity professionals who are trying their best to protect their organizations,” said Stu Sjouwerman, CEO, KnowBe4. “But I think we are starting to see more of a focus on the human element, including human behavior, of cybersecurity protection measures. This is a positive shift in direction because people can implement all of the technical tools and controls in the world, but if they do not focus their efforts on the human layer of security, they are going to run into challenges. At the end of the day, a strong security culture is what truly matters and what we will see organizations focused on as we move into 2022.”

The predicted trends were collected from KnowBe4’s global team of security awareness advocates who are experts with decades of experience in the cybersecurity field. For more information on KnowBe4’s team of experts, visit https://www.knowbe4.com/security-awareness-training-advocates .

About KnowBe4

KnowBe4, the provider of the world’s largest security awareness training and simulated phishing platform, is used by more than 44,000 organizations around the globe. Founded by IT and data security specialist, Stu Sjouwerman, KnowBe4 helps organizations address the human element of security by raising awareness about ransomware, CEO fraud, and other social engineering tactics through a new-school approach to awareness training on security. Kevin Mitnick, an internationally recognized cybersecurity specialist and KnowBe4's Chief Hacking Officer, helped design the KnowBe4 training based on his well-documented social engineering tactics. Tens of thousands of organizations rely on KnowBe4 to mobilize their end users as their last line of defense.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Polpharma Biologics Confirms U.S. Launch of Tyruko® (natalizumab), the First and Only Biosimilar for Multiple Sclerosis17.11.2025 08:52:00 CET | Press release

Polpharma Biologics, a biopharmaceutical company group focused on biosimilars development and manufacturing, today confirmed that Sandoz Tyruko® (natalizumab-sztn) is now available to patients in the United States. Tyruko® is the first and only FDA-approved biosimilar of natalizumab for the treatment of relapsing forms of multiple sclerosis (MS), and also for adult patients with moderately to severely active Crohn’s disease1. Tyruko® was developed by Polpharma Biologics and will be commercialized in the U.S. by its collaboration partner Sandoz, under an exclusive global license agreement. The launch marks a significant milestone in expanding access to high-quality, affordable treatment options for patients living with MS and Crohn’s disease in the United States. Emmanuelle Lepine, Chair of the Supervisory Board, Polpharma Biologics, commented: "The U.S. launch of Tyruko® marks a pivotal moment not only for Polpharma Biologics, but for patients across the United States. This milestone r

Lone Star Acquires Multi-Asset Real Estate Portfolio from St. James’s Place17.11.2025 08:01:00 CET | Press release

Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Real Estate Fund VII, L.P. has successfully completed the acquisition of a multi-asset real estate portfolio from St. James’s Place (SJP) and its Property Unit Trust and Life and Pensions Trust. SJP was advised by Invesco Real Estate, the global real estate investment manager, on the sale of the portfolio. The portfolio comprises 16 high-quality assets across the UK, including multi-let industrial (“MLI”), retail, and office properties. The largest component is the MLI portfolio, which consists of 10 separate property assets predominantly located in Greater London and South East England, and offering access to major transportation and industrial hubs — making them highly attractive for last-mile delivery and regional distribution. The office properties are all situated in London, while the retail assets consist of high-quality retail warehouses with strong tenant bases. Lone Star will implement an active asset

Bureau Veritas appoints Santiago Arias Duval as Executive Vice-President for the Americas region17.11.2025 08:00:00 CET | Press release

Bureau Veritas, a global leader in Testing, Inspection and Certification (TIC), is pleased to announce the appointment of Santiago Arias Duval, effective November 17th, 2025, as Executive Vice-President, Americas. This appointment is in line with Bureau Veritas’ new operating model effective since September 1st, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251116192035/en/ Hinda Gharbi, CEO at Bureau Veritas Bureau Veritas is evolving the structure of its executive committee to drive greater organizational alignment. This organization will empower the regions with scalable Product Lines, enabling global solutions development, and will be unlocking wider cross-selling opportunities. The Americas region is created to leverage fast developing market opportunities across countries in North, Central and South America. This is a dynamic region for all Bureau Veritas where the group intends to expand its leadership across p

Incyte Announces Positive CHMP Opinion for Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma (FL)17.11.2025 07:00:00 CET | Press release

Pending the European Commission decision, Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide will represent an important new therapeutic option from second line for patients with follicular lymphoma (FL) in EuropeIn Western countries, relapsed or refractory FL affects 2-4 out of every 100,000 people1The positive Committee for Medicinal Products for Human Use (CHMP) recommendation is based on data from the Phase 3 inMIND trial which showed patients with relapsed or refractory FL achieved significantly improved progression-free survival with Minjuvi in combination with rituximab and lenalidomide2 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Minjuvi® (tafasitamab) in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at

ASDS 2025: Compelling New Data on Restylane, Sculptra and Relfydess Highlight Galderma’s Innovative Injectable Aesthetics Portfolio and Pipeline17.11.2025 07:00:00 CET | Press release

At ASDS 2025, Galderma unveiled pivotal new data from its range of pioneering Restylane® hyaluronic acid (HA) injectables, highlighting its versatility in improving the chin profile with Restylane Lyft™, temple volume with investigational Restylane Contour™* and skin quality in the décolletage (neckline) with investigational Restylane Skinboosters™*1-3 Nine-month results from a first-of-its-kind clinical trial were presented, reinforcing that the treatment regimen of Restylane Lyft or Restylane Contour with Sculptra® delivers sustained aesthetic facial improvements for patients experiencing facial aesthetic changes after medication-driven weight loss4 The company also presented new phase III data on its investigational product Relfydess™ (RelabotulinumtoxinA)* relating to its rapid onset as early as day one and long duration of effect on frown lines and crow’s feet5 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that it presented new data from its Inje

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye